Micronized 17B-estradiol

Phase 2/3Completed

1 views this week 0 watching💤 Quiet

Interest: 38/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Atherosclerosis

Conditions

Atherosclerosis, Postmenopause

Trial Timeline

Apr 1, 1994 → Nov 1, 1998

NCT ID

NCT00115024

About Micronized 17B-estradiol

Micronized 17B-estradiol is a phase 2/3 stage product being developed by Johnson & Johnson for Atherosclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00115024. Target conditions include Atherosclerosis, Postmenopause.

What happened to similar drugs?

8 of 20 similar drugs in Atherosclerosis were approved

Approved (8) Terminated (3) Active (10)

🔄Orforglipron + PlaceboEli LillyPhase 3

🔄Olmesartan medoxomil + PlaceboDaiichi SankyoPhase 3

🔄Bempedoic acid + Ezetimibe + Rosuvastatin + AtorvastatinDaiichi SankyoPhase 3

✅Rosuvastatin + placebo + aspirin + placeboAstraZenecaApproved

✅Rosuvastatin + PlaceboAstraZenecaApproved

🔄Rosuvastatin + AtorvastatinAstraZenecaPhase 3

🔄Rosuvastatin + PlaceboAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00115024	Phase 2/3	Completed	Apr 1, 1994	Nov 1, 1998	Atherosclerosis

Competing Products

20 competing products in Atherosclerosis

See all competitors

Product	Company	Stage	Hype Score
Orforglipron + Placebo	Eli Lilly	Phase 3	47
Olmesartan medoxomil + Placebo	Daiichi Sankyo	Phase 3	40
Pactimibe sulfate	Daiichi Sankyo	Phase 2/3	30
Pactimibe	Daiichi Sankyo	Phase 2	35
Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin	Daiichi Sankyo	Phase 3	47
Rosuvastatin + placebo + aspirin + placebo	AstraZeneca	Approved	43
Rosuvastatin + Placebo	AstraZeneca	Approved	35
rosuvastatin + placebo	AstraZeneca	Phase 1	29
Rosuvastatin + Placebo	AstraZeneca	Phase 1	29
Rosuvastatin + Atorvastatin	AstraZeneca	Phase 3	40
Rosuvastatin + Placebo	AstraZeneca	Phase 3	40
Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mg	AstraZeneca	Approved	39
Vorapaxar + Placebo	Merck	Phase 3	40
Vorapaxar + Placebo + Aspirin + Clopidogrel	Merck	Phase 2	35
Niacin/simvastatin compared to simvastatin alone at 2 doses	Merck	Approved	43
lovastatin	Merck	Phase 2/3	38
Ezetimibe + Placebo	Merck	Approved	43
Vorapaxar + Placebo	Merck	Phase 3	32
Niaspan	Merck	Pre-clinical	22
MK0633	Merck	Phase 2	35